« Return to News | Clinical Intelligence

Tasimelteon could reset body’s clock in sleep-wake disorder

Friday, January 27, 2012 02:17 PM

Vanda Pharmaceuticals’ compound tasimelteon has shown for the first time to reset the body clock and to align it to a constant 24-hour day in patients suffering from Non-24-Hour Sleep-Wake Disorder. Tasimelteon is a circadian regulator in development for the treatment of the sleep-wake disorder in completely blind individuals with no light perception.

This observation was made in four patients during the initial run-in segment of the RESET study.  RESET is a phase III study of the maintenance effect of tasimelteon in the treatment of Non-24-Hour Sleep-Wake Disorder, which affects over 50% of all completely blind individuals in the U.S. Vanda intends to enroll a total of 20 tasimelteon responders in this study.

Circadian regulation is necessary for the treatment of the disorder and is predictive of a beneficial effect on both nighttime sleep and daytime naps. While light resets the body clock in sighted individuals, keeping it synchronized with the 24-hour day, this effect is lost in completely blind individuals with no light perception.

Vanda is currently studying the efficacy of tasimelteon in Non-24-Hour Sleep-Wake Disorder in two phase III studies, SET and RESET, which are ongoing and expected to be completed by the end of 2012.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.